Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis
Primary Purpose
Diarrhea
Status
Completed
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
oral rehydration solution Hipp ORS Apple 200
ESPGHAN ORS
Sponsored by
About this trial
This is an interventional treatment trial for Diarrhea focused on measuring diarrhea
Eligibility Criteria
Inclusion Criteria:
- children age 4 to 48 months
- diarrhoea defined as the passage of three or more loose or watery stools per day for >1 but <5 days
- mild (3%) or moderate dehydration (3-9%) according to the World Health Organization criteria (Table 1)
- informed consent signed by at least one parent / caregiver
Exclusion Criteria:
- diarrhea for <1 or >5 days
- severe dehydration (>9%)
- recent history of diarrhea indicated either by parent/guardian or hospital case notes
- underlying chronic gastrointestinal disease (i.e., celiac disease, cow's milk protein intolerance)
- breastfeeding >50%
- under nutrition (weight/height ratio below the fifth percentile)
- systemic infections
- immune defects or immunosuppressive treatment
Sites / Locations
- Department of Peadiatrics, The Medical University of Warsaw
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Hipp ORS Apple 200
ESPGHAN ORS
Arm Description
oral rehydration solution Hipp ORS 200 Apple
ESPGHAN oral rehydration solution
Outcomes
Primary Outcome Measures
Number of Participants That Were Successfully Rehydrated
The following components are included in primary outcome:
resolution of signs of dehydration
adequate weight gain
production of urine output during the trial
Secondary Outcome Measures
Unscheduled Intravenous Therapy
Need for intravenous therapy within 24 hours
Vomiting
Vomiting starting or progressing in the first 24 hours of therapy
ORS Intake in ml
ORS intake in ml (in the first 24 hours, and total)
Weight Gain in Gram
Weight gain in gram (in the first 24 hours, and total)
Duration of Diarrhea (Hrs)
Time of diarrhea in hours
Return Visit to the Emergency Department
Return visit to the emergency department within a week
Hospitalization
need for hospitalization within a week
Adverse Events
any adverse event, providing a description if related or not related to study intervention
ORS Intake at 4 h
% of prescribed ORS that was consumed during first 4 hours
Full Information
NCT ID
NCT01467570
First Posted
October 27, 2011
Last Updated
February 14, 2014
Sponsor
Medical University of Warsaw
1. Study Identification
Unique Protocol Identification Number
NCT01467570
Brief Title
Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis
Official Title
Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis: Randomized, Double-Blind Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
It is generally recommended that oral rehydration should be used as first-line therapy to treat or prevent dehydration in children with acute gastroenteritis (AGE). Refusal to drink regular Oral Rehydration Solution (ORS) interfere with compliance with the recommended treatment.
The objective of this study is to compare the tolerance, acceptance, efficacy and safety of a new ORS (Hipp ORS 200 Apple) of improved palatability with regular ORS recommended by ESPGHAN in children with acute gastroenteritis (AGE).
Detailed Description
It is generally recommended that oral rehydration should be used as first-line therapy to treat or prevent dehydration in children with acute gastroenteritis (AGE). Despite the proven efficacy of oral rehydration therapy it remains underused. The main reason for this is that an ORS neither reduces the frequency of bowel movements and fluid loss nor shortens the duration of illness, which decreases its acceptance. Moreover, unpalatability of regular ORS decrease its acceptance, especially in children with lower degrees of dehydration. Refusal to drink regular ORS interfere with compliance with the recommended treatment. Parents, but also health care professionals, demand safe, effective, inexpensive, but also well tolerated and accepted ORS for management of AGE.
Recently, a new ORS (Hipp ORS 200 Apple) with improved taste has been developed, and is now frequently employed for the management of AGE. The proposed study will be the first double-blind randomized trial of this ORS. It will evaluate clinically meaningful benefits to be derived by children and caregivers from its use. If positive, this new ORS may become a routine recommendation for children with AGE.
The objective of this study is to compare the tolerance, acceptance, efficacy and safety of a new ORS (Hipp ORS 200 Apple) with regular ORS recommended by ESPGHAN in children with AGE.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea
Keywords
diarrhea
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
147 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hipp ORS Apple 200
Arm Type
Experimental
Arm Description
oral rehydration solution Hipp ORS 200 Apple
Arm Title
ESPGHAN ORS
Arm Type
Active Comparator
Arm Description
ESPGHAN oral rehydration solution
Intervention Type
Dietary Supplement
Intervention Name(s)
oral rehydration solution Hipp ORS Apple 200
Intervention Description
Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)
Intervention Type
Dietary Supplement
Intervention Name(s)
ESPGHAN ORS
Intervention Description
Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)
Primary Outcome Measure Information:
Title
Number of Participants That Were Successfully Rehydrated
Description
The following components are included in primary outcome:
resolution of signs of dehydration
adequate weight gain
production of urine output during the trial
Time Frame
Proportion of successfully rehydrated at 24 hours
Secondary Outcome Measure Information:
Title
Unscheduled Intravenous Therapy
Description
Need for intravenous therapy within 24 hours
Time Frame
24 hours
Title
Vomiting
Description
Vomiting starting or progressing in the first 24 hours of therapy
Time Frame
24 hours
Title
ORS Intake in ml
Description
ORS intake in ml (in the first 24 hours, and total)
Time Frame
24 hours
Title
Weight Gain in Gram
Description
Weight gain in gram (in the first 24 hours, and total)
Time Frame
24 hours
Title
Duration of Diarrhea (Hrs)
Description
Time of diarrhea in hours
Time Frame
7days
Title
Return Visit to the Emergency Department
Description
Return visit to the emergency department within a week
Time Frame
1 week
Title
Hospitalization
Description
need for hospitalization within a week
Time Frame
1 week
Title
Adverse Events
Description
any adverse event, providing a description if related or not related to study intervention
Time Frame
24 hours
Title
ORS Intake at 4 h
Description
% of prescribed ORS that was consumed during first 4 hours
Time Frame
4 hrs
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Months
Maximum Age & Unit of Time
48 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
children age 4 to 48 months
diarrhoea defined as the passage of three or more loose or watery stools per day for >1 but <5 days
mild (3%) or moderate dehydration (3-9%) according to the World Health Organization criteria (Table 1)
informed consent signed by at least one parent / caregiver
Exclusion Criteria:
diarrhea for <1 or >5 days
severe dehydration (>9%)
recent history of diarrhea indicated either by parent/guardian or hospital case notes
underlying chronic gastrointestinal disease (i.e., celiac disease, cow's milk protein intolerance)
breastfeeding >50%
under nutrition (weight/height ratio below the fifth percentile)
systemic infections
immune defects or immunosuppressive treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hania Szajewska, Professor
Organizational Affiliation
Medical University of Warsaw
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Peadiatrics, The Medical University of Warsaw
City
Warsaw
ZIP/Postal Code
01-183
Country
Poland
12. IPD Sharing Statement
Citations:
PubMed Identifier
18493225
Citation
Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H; ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert Working Group. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr. 2008 May;46(5):619-21. doi: 10.1097/MPG.0b013e31816e219e. No abstract available.
Results Reference
background
PubMed Identifier
1573500
Citation
Recommendations for composition of oral rehydration solutions for the children of Europe. Report of an ESPGAN Working Group. J Pediatr Gastroenterol Nutr. 1992 Jan;14(1):113-5. No abstract available.
Results Reference
background
PubMed Identifier
10817282
Citation
Szajewska H, Hoekstra JH, Sandhu B; ESPGHAN Working Group on Acute Diarrhoea. Management of acute gastroenteritis in Europe and the impact of the new recommendations: a multicenter study. The Working Group on acute Diarrhoea of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2000 May;30(5):522-7. doi: 10.1097/00005176-200005000-00011.
Results Reference
background
PubMed Identifier
22860693
Citation
Piescik-Lech M, Szymanski H, Szajewska H. Efficacy and safety of a new apple-flavoured oral rehydration solution in children with acute gastroenteritis: a double-blind randomized controlled trial. Acta Paediatr. 2012 Oct;101(10):e458-64. doi: 10.1111/j.1651-2227.2012.02782.x. Epub 2012 Aug 3.
Results Reference
derived
Learn more about this trial
Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis
We'll reach out to this number within 24 hrs